Korean Cosmetic IP Strategy: Formulation, Delivery, Packaging, MFDS

Cosmetics rarely fit into a single IP basket. The valuable assets — actives and ratios, delivery vehicles, package shape, brand identity, regulatory data — sit across different rights. In Korea, a complete portfolio combines KIPO patents and design rights, KIPO trademarks, and MFDS (Ministry of Food and Drug Safety) functional cosmetic review. This article maps each layer and explains why reverse-engineering risk makes a parallel trade-secret strategy mandatory.

Five things you can protect in cosmetics

1. Composition patents — Korean drafting form

A composition patent protects new combinations or ratios. KIPO's claim drafting guide shows the standard form: "a composition consisting of 40-60 wt% A, 30-50 wt% B, and 20-30 wt% C." Concentration ranges are stated for each ingredient.

Compositions can be claimed as "comprising" (open-ended) or "consisting of" (closed). Open-ended is broader but harder to defend on novelty/inventive step; closed is narrower but easier to differentiate. A common pattern: register the closed form first for stability, then push the open-ended claim through a divisional.

2. Delivery vehicles and process patents

The same actives behave very differently depending on microencapsulation, liposomes, nano-emulsions, or SLN (solid lipid nanoparticles). Vehicles and processes are hard to reverse-engineer and frequently kept as trade secrets, but novel ones merit patent protection too — better licensing leverage and standards positioning. Standard claim forms: "a cosmetic composition comprising a delivery vehicle of particle size X" or "a method of preparing a cosmetic composition comprising the steps of …".

3. Containers and packaging — design registration

Bottles, tubes, caps, and overall package shape are protected via the Design Protection Act. Cosmetic packaging falls in Locarno class 9, eligible for the partial-examination track — registration in 4-6 months, ideal for K-beauty's seasonal cadence. Use "basic design + related designs" to cover variants in the same family.

4. Brand — trademarks and trade dress

Brand names and logos register in NICE class 3 (cosmetics); add class 35 (cosmetics retail) for marketplace and offline coverage. The US and EU recognize trade dress for distinctive packaging and shelf presence; Korea doesn't have a standalone trade-dress system, but the Unfair Competition Prevention Act protects "product shape imitation" within limits. Pair brand-critical items with trademark + design + 3D trademark for layered defense.

5. MFDS functional cosmetic review

To advertise claims like whitening, anti-wrinkle, UV protection, hair-loss relief in Korea, you need MFDS functional cosmetic review (or notification) under the Functional Cosmetic Review regulation. The dossier covers origin and development history, safety (toxicity, irritation, sensitization), efficacy (in-vitro and human application), and standards/test methods — typically a 6-12 month review.

This regulatory dossier overlaps heavily with patent inventive-step / efficacy data, so running the patent application and the MFDS review in parallel sharing data work pays off. But novelty rules say file the patent before or simultaneously with any public-facing MFDS step — leaked review materials become self-disclosure that can defeat your own patent.

Recommended layering — four phases

1. Phase 1 (R&D): file a Korean provisional application for the actives and delivery vehicle — secure a priority date even before the spec is final
2. Phase 2 (6-10 months pre-launch): file the regular composition / process patent + design registration for the container
3. Phase 3 (right before launch): file the trademark (NICE 3 + 35) and start MFDS functional review
4. Phase 4 (post-launch): stand up the trade-secret program — NDAs, access control, original-record verification for processes and exact ratios

Frequently asked questions

Should I list exact ingredient percentages in the claim?

Stating percentage ranges is standard, e.g. "A 1-5 wt%, B 0.1-2 wt%." Provide a tighter optimal sub-range in the spec ("preferably 2-3 wt%") so you can step-down narrow during disputes.

Who is the inventor in a K-beauty OEM context?

Inventorship turns on substantive contribution. If the brand company supplies only the concept and requirements while the OEM develops the formulation, the OEM staff are the inventors. Ownership transfers only by contract — without a clear "all IP arising from development is assigned to brand" clause in the OEM agreement, the OEM holds the rights. A frequent source of disputes.

Should I include efficacy data in the patent spec?

Yes — it strengthens the inventive-step argument by demonstrating clear effects. Just remember anything in the published spec is public, so split: disclosable data (human-application results) goes in the spec; process know-how and exact internal ratios stay as trade secrets.